Cited by 202SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesVaccine Coverage and Hesitancy

The DOI matches its Crossref record; 29 of the 31 references it cites were found in a registry or an index.

Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020–May 2021

Open access

Jones, Jefferson M., Stone, Mars, Sulaeman, Hasan, Fink, Rebecca V., Dave, Honey, Levy, Matthew E., Di Germanio, Clara, Green, Valerie, Notari, Edward, Saa, Paula, Biggerstaff, Brad J., Strauss, Donna, Kessler, Debra, Vassallo, Ralph, Reik, Rita, Rossmann, Susan, Destree, Mark, Nguyen, Kim-Anh, Sayers, Merlyn, Lough, Chris, Bougie, Daniel W., Ritter, Megan, Latoni, Gerardo, Weales, Billy, Sime, Stacy, Gorlin, Jed, Brown, Nicole E., Gould, Carolyn V., Berney, Kevin, Benoit, Tina J., Miller, Maureen J., Freeman, Dane, Kartik, Deeksha, Fry, Alicia M., Azziz-Baumgartner, Eduardo, Hall, Aron J., MacNeil, Adam, Gundlapalli, Adi V., Basavaraju, Sridhar V., Gerber, Susan I., Patton, Monica E., Custer, Brian, Williamson, Phillip, Simmons, Graham, Thornburg, Natalie J., Kleinman, Steven, Stramer, Susan L., Opsomer, Jean, Busch, Michael P.·2021·JAMA

DOI 10.1001/jama.2021.15161PMC PMC8414359

Open this paper in CoChat — free account Open PDF

Abstract

Importance: People who have been infected with or vaccinated against SARS-CoV-2 have reduced risk of subsequent infection, but the proportion of people in the US with SARS-CoV-2 antibodies from infection or vaccination is uncertain. Objective: To estimate trends in SARS-CoV-2 seroprevalence related to infection and vaccination in the US population. Design, Setting, and Participants: In a repeated cross-sectional study conducted each month during July 2020 through May 2021, 17 blood collection organizations with blood donations from all 50 US states; Washington, DC; and Puerto Rico were organized into 66 study-specific regions, representing a catchment of 74% of the US population. For each study region, specimens from a median of approximately 2000 blood donors were selected and tested each month; a total of 1 594 363 specimens were initially selected and tested. The final date of blood donation collection was May 31, 2021. Exposure: Calendar time. Main Outcomes and Measures: Proportion of persons with detectable SARS-CoV-2 spike and nucleocapsid antibodies. Seroprevalence was weighted for demographic differences between the blood donor sample and general population. Infection-induced seroprevalence was defined as the prevalence of the population with both spike and nucleocapsid antibodies. Combined infection- and vaccination-induced seroprevalence was defined as the prevalence of the population with spike antibodies. The seroprevalence estimates were compared with cumulative COVID-19 case report incidence rates. Results: Among 1 443 519 specimens included, 733 052 (50.8%) were from women, 174 842 (12.1%) were from persons aged 16 to 29 years, 292 258 (20.2%) were from persons aged 65 years and older, 36 654 (2.5%) were from non-Hispanic Black persons, and 88 773 (6.1%) were from Hispanic persons. The overall infection-induced SARS-CoV-2 seroprevalence estimate increased from 3.5% (95% CI, 3.2%-3.8%) in July 2020 to 20.2% (95% CI, 19.9%-20.6%) in May 2021; the combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% (95% CI, 82.9%-83.7%). By May 2021, 2.1 SARS-CoV-2 infections (95% CI, 2.0-2.1) per reported COVID-19 case were estimated to have occurred. Conclusions and Relevance: Based on a sample of blood donations in the US from July 2020 through May 2021, vaccine- and infection-induced SARS-CoV-2 seroprevalence increased over time and varied by age, race and ethnicity, and geographic region. Despite weighting to adjust for demographic differences, these findings from a national sample of blood donors may not be representative of the entire US population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2021.15161

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · doi:10.1101/2021.06.21.21258528 · Cited by 1,163
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
Variance estimation for complex surveys using replication techniques
Rust, K., & Rao, J. (1996) · Statistical Methods in Medical Research · doi:10.1177/096228029600500305 · Cited by 662
Association of Social and Demographic Factors with COVID-19 Incidence and Death Rates in the US
Karmakar, M., Lantz, P. M., & Tipirneni, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36462 · Cited by 580
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Bajema, K. L., Wiegand, R. E., Cuffe, K. M., Patel, S. V., Iachan, R., Lim, T. W., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 272
Self-citation
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study
Anand, S., Montez‐Rath, M. E., Han, J., Bozeman, J., KERSCHMANN, R. L., Beyer, P., Parsonnet, J., & Chertow, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32009-2 · Cited by 265
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265

Show all 31 references

Research works printed but not linked: 1

Petersen, Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected persons., Clin Infect Dis

Sorted by citations

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298
SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Pilz, S., Theiler‐Schwetz, V., Trummer, C., Krause, R. G. E., & Ioannidis, J. P. A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112911 · Cited by 273
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02219-5 · Cited by 198
Understanding T cell responses to COVID-19 is essential for informing public health strategies
Vardhana, S. A., Baldo, L., Morice, W. G., & Wherry, E. J. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo1303 · Cited by 140
Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022
Jones, J. M., Manrique, I. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Spencer, B. R., Notari, E. P., Bravo, M. D., Lanteri, M. C., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7222a3 · Cited by 141
Self-citation
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Follmann, D. A., Janes, H., Buhule, O. D., Zhou, H., Girard, B., Marks, K., Kotloff, K. L., Desjardins, M., Corey, L., Neuzil, K. M., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1300 · Cited by 127
Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: a global systematic review and meta-analysis of over 200 million study participants
Irizar, P., Pan, D., Kapadia, D., Bécares, L., Sze, S., Taylor, H. F. W., Amele, S., Kibuchi, E., Divall, P., Gray, L. J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101877 · Cited by 109
Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children
Xu, Q., Milanez‐Almeida, P., Martins, A. J., Radtke, A. J., Hoehn, K. B., Oguz, C., Chen, J., Liu, C., Tang, J., Grubbs, G., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01367-z · Cited by 82
Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021
Jones, J. M., Opsomer, J. D., Stone, M., Benoit, T. J., Ferg, R., Stramer, S. L., & Busch, M. P. (2022) · JAMA · doi:10.1001/jama.2022.9745 · Cited by 61
Self-citation
Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19
Alejo, J. L., Mitchell, J., Chang, A. Y., Chiang, T. P., Massie, A. B., Segev, D. L., & Makary, M. A. (2022) · JAMA · doi:10.1001/jama.2022.1393 · Cited by 56
The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023
Murphy, T. J., Swail, H., Jain, J., Anderson, M., Awadalla, P., Behl, L., Brown, P. E., Charlton, C. L., Colwill, K., Drews, S. J., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230249 · Cited by 52
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022
Wiegand, R. E., Deng, Y., Deng, X., Lee, A., Meyer, W. A., Letovsky, S. I., Charles, M. D., Gundlapalli, A. V., MacNeil, A., Hall, A. J., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100403 · Cited by 55
Self-citation
Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
Deng, L., Li, P., Zhang, X., Jiang, Q., Turner, D. E., Zhou, C., Gao, Y., Qian, F., Zhang, C., Lu, H. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24220-7 · Cited by 50
The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric ( REDS‐IV‐P ): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Josephson, C. D., Glynn, S. A., Mathew, S., Birch, R., Bakkour, S., Kreuziger, L. B., Busch, M. P., Chapman, K., Dinardo, C. L., Hendrickson, J. E., et al. (2022) · Transfusion · doi:10.1111/trf.16869 · Cited by 45
Self-citation
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design
Ayoub, H. H., Tomy, M., Chemaitelly, H. S., Altarawneh, H. N., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad239 · Cited by 40
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States
Fusco, M. D., Marczell, K., Deger, K. A., Moran, M. M., Wiemken, T. L., Cane, A. D., de Boisvilliers, S., Yang, J., Vaghela, S., & Roïz, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2071427 · Cited by 41
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin
Volk, A., Covini-Souris, C., Kühnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00511-9 · Cited by 35
Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection–Induced Seroprevalence: A Nationwide Blood Donor Study—United States, July 2020–June 2021
Li, Z., Lewis, B. E., Berney, K., Hallisey, E. J., Williams, A. M., Whiteman, A., Rivera-González, L. O., Clarke, K. E. N., Clayton, H. B., Tincher, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac105 · Cited by 36
Self-citation
Red Blood Cell Storage: From Genome to Exposome Towards Personalized Transfusion Medicine
D’Alessandro, A., & Hod, E. A. (2023) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2023.150750 · Cited by 35
Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain
Karachaliou, M., Moncunill, G., Espinosa, A., Castaño‐Vinyals, G., Jiménez, A., Vidal, M., Santano, R., Barrios, D., Puyol, L., Carreras, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00807-4 · Cited by 36
SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022
Akinbami, L. J., Kruszon‐Moran, D., Wang, C., Storandt, R., Clark, J., Riddles, M. K., & Mohadjer, L. K. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7148a4 · Cited by 33
Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic
Tomov, L., Chervenkov, L., Miteva, D., Batselova, H., & Velikova, T. V. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i29.6974 · Cited by 47
Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021
Busch, M. P., Stramer, S. L., Stone, M., Yu, E. A., Grebe, E., Notari, E. P., Saá, P., Ferg, R., Manrique, I. M., Weil, N., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac470 · Cited by 30
Self-citation
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
Castilla, J., Lecea, Ó., Martín Salas, C., Quílez, D., Miqueleiz, A., Trobajo-Sanmartín, C., Navascués, A., Martínez-Baz, I., Casado, I., Burgui, C., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.33.2200619 · Cited by 31
Point Prevalence Estimates of Activity-Limiting Long-term Symptoms Among United States Adults ≥1 Month After Reported Severe Acute Respiratory Syndrome Coronavirus 2 Infection, 1 November 2021
Tenforde, M. W., Devine, O. J., Reese, H. E., Silk, B. J., Iuliano, A. D., Threlkel, R., Quan, V. M., Plumb, I. D., Cadwell, B. L., Rose, C. E., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac281 · Cited by 26
Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design
Ayoub, H. H., Tomy, M., Chemaitelly, H., Altarawneh, H. N., Coyle, P., Tang, P., Hasan, M. R., Kanaani, Z. A., Kuwari, E. A., Butt, A. A., et al. (2022) · doi:10.1101/2022.01.02.22268622 · Cited by 41
On the Uses and Abuses of Regression Models: A Call for Reform of Statistical Practice and Teaching
Carlin, J. B., & Moreno‐Betancur, M. (2025) · Statistics in Medicine · doi:10.1002/sim.10244 · Cited by 37
Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 25
Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma
Saá, P., Fink, R. V., Bakkour, S., Jin, J., Simmons, G., Muench, M. O., Dawar, H., Germanio, C. D., Hui, A. J., Wright, D. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159876 · Cited by 26
Self-citation
Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases
Bloch, E. M., Busch, M. P., Corash, L., Dodd, R. Y., Hailu, B., Kleinman, S. H., O’Brien, S. F., Petersen, L. R., Stramer, S. L., & Katz, L. M. (2023) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2023.150769 · Cited by 26
Self-citation
Estimation of SARS-CoV-2 Infection Fatality Rate by Age and Comorbidity Status Using Antibody Screening of Blood Donors During the COVID-19 Epidemic in Denmark
Kaspersen, K. A., Hindhede, L., Boldsen, J. K., Mikkelsen, S., Vestergaard, L. S., Berthelsen, A.-S. N., Moustsen‐Helms, I. R., Holm, D. K., Nilsson, A. C., Sækmose, S. G., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab566 · Cited by 25
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N. A., Allen, M., Antony, J., Asante, K. P., Bhate, A. S., Beresnev, T. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00263-1 · Cited by 40
Effects of Climate Change on Plant Diseases
Priya, R. S., Yuvaraj, M., Sharmila, R. B., Jagathjothi, N., Saranya, M., Suganthi, N., Subramanian, K. S., Deivamani, M., Cyriac, J., Arthanari, P. M., et al. (2024) · Springer eBooks · doi:10.1007/978-3-031-56011-8_7 · Cited by 24
Infectious disease surveillance needs for the United States: lessons from Covid-19
Lipsitch, M., Bassett, M. T., Brownstein, J. S., Elliott, P., Eyre, D. W., Grabowski, M. K., Hay, J. A., Johansson, M. A., Kissler, S. M., Larremore, D. B., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1408193 · Cited by 29
Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors
Grebe, E., Stone, M., Spencer, B. R., Akinseye, A., Wright, D. J., Germanio, C. D., Bruhn, R. L., Zurita, K. G., Contestable, P., Green, V., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3008.240659 · Cited by 24
Self-citation
Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses
Pisanic, N., Antar, A. A. R., Kruczynski, K. L., Rivera, M. G., Dhakal, S., Spicer, K., Randad, P. R., Pekosz, A. S., Klein, S. L., Betenbaugh, M. J., et al. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113440 · Cited by 21
Maternal and Perinatal Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy, Florida, 2020–2021: A Retrospective Cohort Study
Doyle, T. J., Egziabher-Kiros, G., Schmitt-Matzen, E. N., Propper, R., Thompson, A. Y., & Phillips-Bell, G. S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac441 · Cited by 20
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era
Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20
MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection
Byrum, J. R., Waltari, E., Janson, O., Guo, S.-M., Folkesson, J., Chhun, B. B., Vinden, J., Ivanov, I. E., Forst, M. L., Li, H., et al. (2023) · Pathogens · doi:10.3390/pathogens12050671 · Cited by 17
Occupations Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination, US Blood Donors, May 2021–December 2021
Shah, M. M., Spencer, B. R., Feldstein, L. R., Haynes, J. M., Benoit, T. J., Saydah, S., Groenewold, M. R., Stramer, S. L., & Jones, J. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac883 · Cited by 18
Self-citation
Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany—Results from the SeBluCo Study 2020–2022
Offergeld, R., Preußel, K., Zeiler, T. A., Aurich, K., Baumann-Baretti, B., Ciesek, S., Corman, V. M., Dienst, V., Drosten, C., Görg, S., et al. (2023) · Pathogens · doi:10.3390/pathogens12040551 · Cited by 18
How do we decide how representative our donors are for public health surveillance?
O’Brien, S. F., Drews, S. J., Lewin, A., Russell, W. A., Davison, K. L., Goldman, M., & International Society for Blood Transfusion, T. T. I. D. W. P. (2022) · Transfusion · doi:10.1111/trf.17140 · Cited by 18
Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection
Nunhofer, V., Weidner, L., Hoeggerl, A. D., Zimmermann, G., Badstuber, N., Grabmer, C., Jungbauer, C., Lindlbauer, N., Held, N., Pascariuc, M., et al. (2022) · Viruses · doi:10.3390/v14030637 · Cited by 17
Patterns of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Among 1.6 Million Blood Donors: Impact of Vaccination, United States, December 2020–June 2021
Dodd, R. Y., Notari, E. P., Brodsky, J. P., Foster, G. A., Xu, M. J., Saá, P., & Stramer, S. L. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab514 · Cited by 16
Self-citation
The (apparent) antibody paradox in COVID-19
Ameratunga, R., Woon, S., Lea, E., Steele, R. H., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2044797 · Cited by 16
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study
Owusu‐Boaitey, N., Russell, T., Meyerowitz‐Katz, G., Levin, A., & Herrera, D. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.21.2200809 · Cited by 13
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2
Ameratunga, R., Woon, S.-T., Steele, R., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2074403 · Cited by 16
Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of Health
O’Brien, S. F., Caffrey, N., Yi, Q., Bolotin, S., Janjua, N. Z., Binka, M., Quach, C., Stein, D. R., Lang, A. L. S., Colquhoun, A., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03356-22 · Cited by 15
Trends and risk factors of SARS‐CoV ‐2 infection in asymptomatic blood donors
Valenti, L. V. C., Pelusi, S., Cherubini, A., Bianco, C., Ronzoni, L., Renteria, S. U., Coluccio, E. B., Berzuini, A., Lombardi, A., Terranova, L., et al. (2021) · Transfusion · doi:10.1111/trf.16693 · Cited by 15
Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection
Hønge, B. L., Hindhede, L., Kaspersen, K. A., Harritshøj, L. H., Mikkelsen, S., Holm, D. K., Nilsson, A. C., Sækmose, S. G., Sørensen, E., Aagaard, B., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.041 · Cited by 15
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection
Schuh, A. J., Satheshkumar, P. S., Dietz, S., Bull–Otterson, L., Charles, M. D., Edens, C., Jones, J. M., Bajema, K. L., Clarke, K. E. N., McDonald, L. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01247-22 · Cited by 15
Self-citation
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Alexopoulos, H., Trougakos, I., Dimopoulos, M., & Terpos, E. (2022) · European journal of internal medicine · doi:10.1016/j.ejim.2022.11.009 · Cited by 14
How do we …form and coordinate a national serosurvey of SARS‐CoV ‐2 within the blood collection industry?
Fink, R. V., Fisher, L., Sulaeman, H., Dave, H., Levy, M. E., McCann, L., Germanio, C. D., Notari, E. P., Green, V., Cyrus, S., et al. (2022) · Transfusion · doi:10.1111/trf.16943 · Cited by 13
Self-citation
Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV)
Germain, M., Lewin, A., Bazin, R., Dieudé, M., Perreault, J., Boivin, A., Grégoire, Y., & Renaud, C. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068803 · Cited by 14
Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States
Haynes, J. M., Dodd, R. Y., Crowder, L. A., Notari, E. P., & Stramer, S. L. (2023) · Emerging infectious diseases · doi:10.3201/eid2907.230173 · Cited by 14
Self-citation
Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022
Kinoshita, R., Arashiro, T., Kitamura, N., Arai, S., Takahashi, K., Suzuki, T., Suzuki, M., & Yoneoka, D. (2023) · Emerging infectious diseases · doi:10.3201/eid2909.230365 · Cited by 13
Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2
Routledge, I., Takahashi, S., Epstein, A., Hakim, J. M. C., Janson, O., Turcios, K., Vinden, J., Risos, J. T., Baniqued, M. R., Pham, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30051-x · Cited by 11
Self-citation
SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron
O’Brien, S. F., Caffrey, N., Yi, Q., Pambrun, C., & Drews, S. J. (2022) · Viruses · doi:10.3390/v14112336 · Cited by 13
Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021
Plumb, I. D., Fette, L. M., Tjaden, A. H., Feldstein, L. R., Saydah, S., Ahmed, A., Link‐Gelles, R., Wierzba, T. F., Berry, A. A., Friedman-Klabanoff, D. J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.006 · Cited by 12
Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications
Sulaeman, H., Grebe, E., Dave, H., McCann, L., Germanio, C. D., Sanghavi, A., Sclar, V., Bougie, D. W., Chatelain, G., Biggerstaff, B. J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03234-22 · Cited by 12
Self-citation
Beyond sex and gender differences: The case for women's health research
Galea, L. A. M., Lee, B. H., de leon, R. G., Rajah, M. N., & Einstein, G. (2023) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-323-88534-8.00045-6 · Cited by 12
Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics
Lee, D., Nande, A., Anderson, T. L., Levy, M. Z., & Hill, A. L. (2025) · Journal of The Royal Society Interface · doi:10.1098/rsif.2024.0689 · Cited by 14
Self-citation
SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May–July 2021
O’Brien, S. C., Cole, L. D., Albanese, B. A., Mahon, A., Knight, V., Williams, N., Severson, R., Burakoff, A. W., Alden, N. B., & Dominguez, S. R. (2023) · Emerging infectious diseases · doi:10.3201/eid2905.221541 · Cited by 11
Predicting SARS-CoV-2 Variant Spread in a Completely Seropositive Population Using Semi-Quantitative Antibody Measurements in Blood Donors
Buss, L., Junior, C. A. P., Whittaker, C., Salomon, T., Oikawa, M. K., Pereira, R. H. M., Moura, I. C. G., Delerino, L., França, R. F. D. O., Miyajima, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10091437 · Cited by 11
Self-citation
Digital transformation and environmental sustainability: reviewing the role of human capital
Saini, M., Singh, D., Kataria, A., & Singh, R. (2025) · Journal of Organizational Change Management · doi:10.1108/jocm-03-2025-0289 · Cited by 13
SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021
Gallian, P., Hozé, N., Brisbarre, N., Villarroel, P. M. S., Nurtop, E., Isnard, C., Pastorino, B. A. M., Richard, P., Morel, P., Cauchemez, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106222 · Cited by 10
Seroprevalence as an Indicator of Undercounting of COVID-19 Cases in a Large Well-Described Cohort
Taylor, K. M., Ricks, K. M., Kuehnert, P. A., Eick-Cost, A. A., Scheckelhoff, M., Wiesen, A. R., Clements, T. L., Hu, Z., Zak, S. E., Olschner, S. P., et al. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100141 · Cited by 10
Who Gets Sick From COVID-19? Sociodemographic Correlates of Severe Adult Health Outcomes During Alpha- and Delta-Variant Predominant Periods: September 2020–November 2021
Wei, S. C., Freeman, D. F., Himschoot, A., Clarke, K. E. N., Dyke, M. E. V., Adjemian, J., Ahmad, F. B., Benoit, T. J., Berney, K., Gundlapalli, A. V., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad357 · Cited by 11
Self-citation
Aseptic Meningitis Following the Second Dose of Comirnaty Vaccination in an Adolescent Patient
Lee, J. K. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003385 · Cited by 10
Qualitative and quantitative detection of SARS-CoV-2 antibodies from dried blood spots
Omosule, C. L., Conklin, J., Seck, S., Howell, R., Hock, K. G., Ballman, C., Freeman, J., du Toit, L., Dubberke, E. R., & Farnsworth, C. W. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.12.012 · Cited by 10
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays
Tuite, A. R., Fisman, D. N., Abe, K. T., Rathod, B., Pasculescu, A., Colwill, K., Gingras, A., Yi, Q., O’Brien, S. F., & Drews, S. J. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02563-21 · Cited by 10
A methods review of the “healthy donor effect” in studies of long‐term health outcomes in blood donors
Rahman, M. M., Karki, S., & Hayen, A. D. (2022) · Transfusion · doi:10.1111/trf.16791 · Cited by 9
Estimating the cumulative incidence of SARS-CoV-2 infection in Costa Rica: modelling seroprevalence data in a population-based cohort
Fantin, R., Agarwala, N., Aparicio, A., Pfeiffer, R. M., Waterboer, T., Abdelnour, A., Butt, J., Flock, J., Remans, K., Prevots, D. R., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100616 · Cited by 9
Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV ‐2 infection and vaccination
Roubinian, N. H., Greene, J., Liu, V. X., Lee, C., Mark, D. G., Vinson, D. R., Spencer, B. R., Bruhn, R. L., Bravo, M. D., Stone, M., et al. (2023) · Transfusion · doi:10.1111/trf.17616 · Cited by 9
Self-citation
Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in Blood Donor Populations
Patel, E. U., Bloch, E. M., & Tobian, A. A. R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab517 · Cited by 9
SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021
Tran, T. N.-A., Wikle, N. B., Yang, F., Inam, H., Leighow, S. M., Gentilesco, B. J., Chan, P. A., Albert, E., Strong, E. R., Pritchard, J. R., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14171 · Cited by 7
COVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States
Freedman, N. D., Brown, L. L., Newman, L. M., Jones, J. M., Benoit, T. J., Averhoff, F. M., Bu, X., Bayrak, K., Lu, A., Coffey, B. D., et al. (2022) · Scientific Data · doi:10.1038/s41597-022-01830-4 · Cited by 9
Self-citation
Blood donor SARS ‐ CoV ‐2 infection or vaccination and adverse outcomes in plasma and platelet transfusion recipients
Roubinian, N. H., Greene, J., Spencer, B. R., Bravo, M. D., Bruhn, R. L., Saá, P., Stone, M., Custer, B., Kleinman, S. H., Liu, V. X., et al. (2025) · Transfusion · doi:10.1111/trf.18159 · Cited by 8
Self-citation
Beyond Vaccination Rates: A Synthetic Random Proxy Metric of Total SARS-CoV-2 Immunity Seroprevalence in the Community
Si, Y., Covello, L., Wang, S., Covello, T., & Gelman, A. (2022) · Epidemiology · doi:10.1097/ede.0000000000001488 · Cited by 8
Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021–July 2021)
Kanji, J. N., Nguyen, L. T., Plitt, S. S., Charlton, C. L., Fenton, J., Braun, S., Marohn, C., Lau, C. K. Y., Svenson, L. W., Hinshaw, D., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2080250 · Cited by 8
Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions
Glasser, J. W., Feng, Z., Vo, M., Jones, J. N., & Clarke, K. E. N. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111296 · Cited by 8
Self-citation
White paper on pandemic preparedness in the blood supply
Strengers, P. F. W., O’Brien, S. F., Politis, C., Mayr, W. R., Seifried, E., & Spencer, B. R. (2022) · Vox Sanguinis · doi:10.1111/vox.13378 · Cited by 8
SARS-CoV-2 Serosurveys: How Antigen, Isotype and Threshold Choices Affect the Outcome
Binder, R. A., Fujimori, G., Forconi, C. S., Reed, G. W., Silva, L. S., Lakshmi, P. S., Higgins, A., Cincotta, L., Dutta, P., Salive, M.-C., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac431 · Cited by 7
Infectious Disease Epidemiology
Straif-Bourgeois, S. C., Tonzel, J. L., Kretzschmar, M., & Ratard, R. C. (2023) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_34-1 · Cited by 7
A quarantine paradox: understanding Gender-Based Violence (GBV) in post-COVID-19 era: insights from Golden Valley mining community, Zimbabwe
Magwegwe, E. (2024) · BMC Public Health · doi:10.1186/s12889-024-20180-x · Cited by 8
Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples
Racey, C. S., Booth, A., Albert, A., Smith, L., Krajden, M., Murray, M. C. M., Côté, H. C. F., Gottschlich, A., Goldfarb, D. A., Sadarangani, M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062567 · Cited by 7
Epidemic time series similarity is related to geographic distance and age structure
Dallas, T., Foster, G., Richards, R. L., & Elderd, B. D. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.09.002 · Cited by 7
Disproportionate impacts of COVID-19 in a large US city
Fox, S. J., Javan, E. M., Pasco, R. F., Gibson, G., Betke, B. A., Herrera, J. L., Woody, S., Pierce, K. A., Johnson, K. E., Johnson-León, M., et al. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011149 · Cited by 8
Seroprevalence of SARS-CoV-2 in Brazil: A systematic review and meta-analysis
Figueiredo, G. M., Tengan, F. M., Campos, S. R. D. S. L. D. C., & Luna, E. J. D. A. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100233 · Cited by 7
Powassan and Eastern Equine Encephalitis Virus Seroprevalence in Endemic Areas, United States, 2019–2020
Padda, H., Huang, C. Y. ‐., Grimm, K. E., Biggerstaff, B. J., Ledermann, J. P., Raetz, J. L., Boroughs, K. L., Mossel, E. C., Martin, S. W., Lehman, J. A., et al. (2025) · Emerging infectious diseases · doi:10.3201/eid3105.240893 · Cited by 6
Self-citation
Investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech Republic: a prospective national cohort study
Thon, V., Piler, P., Pavlík, T., Andrýsková, L., Doležel, K., Kostka, D., Pikhart, H., Bobák, M., & Klánová, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068258 · Cited by 7
Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022
Benoit, T. J., Kim, Y., Deng, Y., Li, Z., Harding, L., Wiegand, R. E., Deng, X., Jones, J. M., Iachan, R., & Clarke, K. E. N. (2024) · Public Health Reports · doi:10.1177/00333549231223140 · Cited by 6
Self-citation
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
García‐Carreras, B., Hitchings, M. D. T., Johansson, M. A., Biggerstaff, M., Slayton, R. B., Healy, J. M., Lessler, J., Quandelacy, T. M., Salje, H., Huang, A. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37944-5 · Cited by 5
Analysis of metapopulation models of the transmission of SARS-CoV-2 in the United States
Vo, M., Feng, Z., Glasser, J. W., Clarke, K. E. N., & Jones, J. N. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01948-y · Cited by 6
Self-citation
Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study
Adams, C., Horton, M. K., Solomon, O., Wong, M. P., Wu, S. L., Fuller, S., Shao, X., Fedrigo, I., Quach, H., Quach, D. L., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000647 · Cited by 7
Self-citation
Demographics of first‐time donors returning for donation during the pandemic: COVID ‐19 convalescent plasma versus standard blood product donors
Buren, N. L. V., Rajbhandary, S., Reynolds, V., Gorlin, J. B., Stramer, S. L., Notari, E. P., Conti, G., Katz, L. M., Stubbs, J. R., van Buskirk, C. M., et al. (2022) · Transfusion · doi:10.1111/trf.17229 · Cited by 6
Self-citation
SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors
Avelino‐Silva, V. I., Bruhn, R. L., Zurita, K. G., Deng, X., Yu, E. A., Grebe, E., Stone, M., Lanteri, M. C., Spencer, B. R., Busch, M. P., et al. (2024) · Transfusion · doi:10.1111/trf.17952 · Cited by 5
Self-citation
Detection of SARS-CoV-2 Reinfections Using Nucleocapsid Antibody Boosting
Grebe, E., Chacreton, D., Stone, M., Spencer, B. R., Haynes, J., Akinseye, A., Lanteri, M. C., Green, V., Sulaeman, H., Bruhn, R. L., et al. (2025) · Emerging infectious diseases · doi:10.3201/eid3105.250021 · Cited by 5
Self-citation
West Nile Virus positivity amongst Canadian blood donors and effectiveness of off‐season screening
Charlton, C. L., Drews, S. J., Makowski, K., Hawes, G., Cranney, C., Robinson, A., Wood, H., Bigham, M., & O’Brien, S. F. (2025) · Transfusion · doi:10.1111/trf.18326 · Cited by 5
A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021
Abe, K. T., Rathod, B., Colwill, K., Gingras, A., Tuite, A. R., Robbins, N. F., Orjuela, G., Jenkins, C., Conrod, V., Yi, Q., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01134-22 · Cited by 5

OA3‐AM23‐ST‐23 | Monitoring Incidence and Seroprevalence of SARS‐CoV‐2 Infections by Vaccine Status Using the US Nationwide Blood Donor Cohort
Jones, J. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Manrique, I. M., Lanteri, M. C., Stramer, S. L., Opsomer, J. D., & Busch, M. P. (2023) · Transfusion · doi:10.1111/trf.30_17554 · Cited by 1
Self-citation
Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program
Stone, M., Germanio, C. D., Wright, D. J., Sulaeman, H., Dave, H., Fink, R. V., Notari, E. P., Green, V., Strauss, D., Kessler, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab537 · Cited by 45
Self-citation
Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
Lewin, A., Serres, G. D., Grégoire, Y., Perreault, J., Drouin, M., Fournier, M., Tremblay, T., Beaudoin, J., Boivin, A., Goyette, G., et al. (2022) · Canadian Journal of Public Health · doi:10.17269/s41997-022-00622-y · Cited by 8
Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021
Busch, M. P., Stramer, S. L., Stone, M., Yu, E. A., Grebe, E., Notari, E. P., Saá, P., Ferg, R., Manrique, I. M., Weil, N., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac470 · Cited by 30
Self-citation
Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022
Jones, J. M., Manrique, I. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Spencer, B. R., Notari, E. P., Bravo, M. D., Lanteri, M. C., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7222a3 · Cited by 141
Self-citation

See all

Authors: Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., Biggerstaff, B. J., Strauss, D., Kessler, D., Vassallo, R., Reik, R., Rossmann, S., Destree, M., Nguyen, K.-A., Sayers, M., Lough, C., Bougie, D. W., Ritter, M., Latoni, G., Weales, B., Sime, S., Gorlin, J., Brown, N. E., Gould, C. V., Berney, K., Benoit, T. J., Miller, M. J., Freeman, D., Kartik, D., Fry, A. M., Azziz-Baumgartner, E., Hall, A. J., MacNeil, A., Gundlapalli, A. V., Basavaraju, S. V., Gerber, S. I., Patton, M. E., Custer, B., Williamson, P., Simmons, G., Thornburg, N. J., Kleinman, S., Stramer, S. L., Opsomer, J., & Busch, M. P.
Affiliations: Centers for Disease Control and Prevention (US)
Vitalant Research Institute (US)
Westat (United States) (US)
Vitalant Research Institute, San Francisco, California
Temple University, Japan (JP)
American Red Cross (US)
Scientific Affairs, American Red Cross, Gaithersburg, Maryland
New York Blood Center (US)
OneBlood (US)
Gulf Coast Regional Blood Center, Houston, Texas
Bloodworks Northwest (US)
Blood Bank of Hawaii, Honolulu
Carter BloodCare (US)
LifeSouth Community Blood Centers, Gainesville, Florida
Versiti Blood Center of Wisconsin (US)
Blood Bank of Alaska, Anchorage
Banco de Sangre de Servicios Mutuos, San Juan, Puerto Rico
The Blood Center, New Orleans, Louisiana
LifeServe, Des Moines, Iowa
Minnesota Historical Society (US)
Georgia Tech Research Institute (US)
COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia
University of British Columbia (CA)
Corresponding author: Jones, Jefferson M.
ORCID: Jones, Jefferson M.
Stone, Mars
Sulaeman, Hasan
Fink, Rebecca V.
Dave, Honey
Levy, Matthew E.
Green, Valerie
Notari, Edward
Biggerstaff, Brad J.
Strauss, Donna
Kessler, Debra
Sayers, Merlyn
Bougie, Daniel W.
Gorlin, Jed
Brown, Nicole E.
Gould, Carolyn V.
Benoit, Tina J.
Miller, Maureen J.
Fry, Alicia M.
Hall, Aron J.
MacNeil, Adam
Gundlapalli, Adi V.
Basavaraju, Sridhar V.
Gerber, Susan I.
Patton, Monica E.
Custer, Brian
Simmons, Graham
Thornburg, Natalie J.
Kleinman, Steven
Stramer, Susan L.
Opsomer, Jean
Busch, Michael P.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2021-10-12
Volume: 326
Issue: 14
Pages: 1400
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2021.15161
PMC: PMC8414359
OpenAlex: W3197430550
Cited by: 201
References: 31
Citations by year: 2026: 13 · 2025: 23 · 2024: 19 · 2023: 57 · 2022: 80 · 2021: 9
FWCI: 13.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: SARS-CoV-2, COVID-19 pandemic, seroprevalence, blood donors, COVID-19 vaccination, SARS-CoV-2 antibodies, spike antibodies, nucleocapsid antibodies, antibody waning, COVID-19 incidence, United States
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serological Testing, Adolescent, Adult, Age Factors, Aged, Antibodies, Viral, Blood Donors, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, United States, Prevalence, Seroepidemiologic Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020–May 2021

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks